The escalating global prevalence of carbapenem-resistant Gram-negative bacteria has significantly constrained therapeutic options, leading to the revived use of polymyxins. However, this resurgence has been paralleled by an increase in reports of associated adverse effects. No case of drug fever induced by polymyxin B (PMB) has been reported in the literature to date. We report the first case of drug fever (≥39 °C) induced by intravenous PMB in a patient with severe pneumonia caused by carbapene